{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-057620","form_type":"8-K","ticker":null,"cik":"0001783032","company_name":"Elevation Oncology, Inc.","filed_at":"2025-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.699694+00:00","generated_at":"2026-05-19T17:24:20.611706+00:00","sec_items":["1.01","5.02","5.07","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Elevation Oncology to be acquired by Concentra for $0.36/share plus CVR; CEO Ferra out","bullets":["Merger with Concentra Biosciences: $0.36 cash per share plus contingent value right (CVR) for up to 80% of net proceeds from EO-1022.","Board unanimously recommends tender; closing requires minimum $26.4M net cash and tender of >50% of outstanding shares.","CEO Joseph Ferra terminated effective June 30; CFO Tammy Furlong appointed President and Interim CEO, receives $600K transaction bonus at closing.","Stockholders approved reverse stock split (1:10–1:50), ratified auditor CohnReznick, and elected three Class I directors.","Tang Capital Partners provides limited guaranty up to $21.4M; support agreements covering ~5.1% of shares secured."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-057620","json":"https://secwatch.observer/filing/0001104659-25-057620.json","markdown":"https://secwatch.observer/filing/0001104659-25-057620.md","text":"https://secwatch.observer/filing/0001104659-25-057620.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783032/000110465925057620/0001104659-25-057620-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783032/000110465925057620/tm2517439d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T17:24:20.611706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64656e898e","claim":"Tammy Furlong was appointed as President and Interim Chief Executive Officer at Elevation Oncology, Inc..","evidence_excerpt":"Effective as of the Separation Date, the Board appointed Tammy Furlong, age 54, the Company’s Chief Financial Officer and Principal Financial and Accounting Officer, to succeed Mr. Ferra as President and Interim Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000110465925057620/0001104659-25-057620-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"cd3f563ccf","claim":"Joseph J. Ferra, Jr. was terminated as President, Chief Executive Officer at Elevation Oncology, Inc..","evidence_excerpt":"In connection with the Merger, the Company terminated the employment of Joseph J. Ferra, Jr., as the Company’s President, Chief Executive Officer, effective as of June 30, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000110465925057620/0001104659-25-057620-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President, Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}